secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001437749-25-034442
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

BioCardia reports Q3 2025 results, $6M financing, and regulatory milestones for cell therapies
--------------------------------------------------------------------------------

- Closed $6.0 million financing with net proceeds of $5.2 million in September 2025.
- Net loss decreased to $1.5 million for Q3 2025 from $1.7 million in Q3 2024.
- Positive preliminary clinical consultation with Japan’s PMDA for CardiAMP heart failure trial.
- Plans to submit Helix transendocardial delivery catheter for FDA DeNovo 510(k) in Q4 2025.
- Cash balance of $5.3 million on Sept 30, 2025, providing runway into Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925034442/0001437749-25-034442-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925034442/bcda20251112_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-034442

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer